009420 — Hanall Biopharma Share News
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩155bn
ChromaDex Corp rises on orphan drug tag to develop treatment for genetic disease
Brief: Hanall Biopharma Signs Licensing Agreement With Turn Biotechnologies
Brief: Hanall Biopharma Q1 Operating Profit 119 Million Won, Swings To Profit From Year Earlier
Australia's Telix Pharmaceuticals hits record high on strong quarter
Brief: Hanall Biopharma Q4 Operating Loss 4 Billion Won, Swings To Loss From Year Earlier
Opko Health tumbles on convertible debt deal
Brief: Hanall Biopharma Q3 Operating Profit 756 Million Won, Down 32% From Year Earlier
Brief: Hanall Biopharma, Daewoong Pharmaceutical And Nurron Pharmaceuticals Initiate First-In-Human Phase 1 Clinical Study Of Hl192
Brief: Hanall Biopharma Q2 Operating Profit 8 Billion Won, Up 1628% From Year Earlier
Acadia rises as brokerages raise stock PT on Daybue drug sales
Zai Lab, Argenx rise as muscle-weakening disease drug gets approval in China
BridgeBio Pharma up on dwarfism therapy trial data
Invest In Vincere Biosciences
Development Agreement With Nurron Pharmaceuticals To Develop Therapy For Parkinson's Disease
Avidity Biosciences gains on brokerage upgrade to 'outperform'
Brief: Hanall Biopharma Announces Results From Phase III Randomized, Double-Masked Active Treatment-Controlled Velos-3 Trial Evaluating Tanfanercept 0.25% For Treatment Of Dry Eye Disease
ARS Pharmaceuticals rises as FDA panel votes in favor of nasal spray
Brief: HanAll Biopharma Reports First Quarter Results
Brief: Hanall Biopharma Q1 Operating Loss 2.3 Billion Won